ASCO 2026 preview – GSK gets an early GIST
Strategist-Frontline is set to begin, as the company reports first-line velzatinib data at ASCO.
Cogent sets the KIT bar for GSK
Bezuclastinib plus Sutent could become standard of care in second-line GIST.
GSK prepares its kit in GIST
The company advances the IDRx-originated KIT inhibitor GSK6042981 into pivotal trials.
The gist of GSK's move is to follow Ono
The UK company buys IRDx for $1bn.
Safety remains in focus for Cogent’s bezuclastinib
An “optimised formulation” of bezuclastinib looks promising, but the safety question remains open.
